eLearning module: The analytics
This expert authored eLearning module focuses on the importance of analytical data during the development process of biosimilars. It also provides a brief overview of the data requirements for approval of these products in Europe.
This module will take up to 20 minutes to complete.
Learning objectives
On completion of the eLearning module, you will be able to:
- Describe how analytical data is utilized in the development of biosimilars.
- Understand the importance of analytics in the EMA approval of biosimilars.
Target audience
All medical oncologists, specialist nurses, and allied healthcare professionals working with patients for whom biosimilars may represent a treatment option.
r Huub Schellekens MD, PhD is emeritus professor of Pharmaceutical Biotechnology at Utrecht University in the Netherlands. He studied medicine at Erasmus University in Rotterdam, The Netherlands ( 1967-1973), where he also did his training in Medical Microbiology (1976-1980) and received his PhD. in 1980.